Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Semalytix GmbH. (11/24/20). "Press Release: Corporate Vice President of Bayer Pharmaceuticals Becomes Advisor to Semalytix". Bielefeld.

Organisations Organisation Semalytix GmbH
  Organisation 2 Bayer Pharmaceuticals Corporation
  Group Bayer (Group)
Products Product AI-based clinical research
  Product 2 drug development
Person Person Jaskolski, Janik (Semalytix 201505– Managing Director + Co-Founder)

Semalytix announced today that Frank Misselwitz, Corporate Vice President of Bayer Pharmaceuticals, is supporting the company in the role of an advisor.

“I am extremely proud to announce today that Frank Misselwitz, Corporate VP of Bayer Pharmaceuticals, will support Semalytix in an advisor role to further our mission to make Patient Centricity a true Northstar KPI in drug development.” says Janik Jaskolski, CEO and co-founder of Semalytix.

Frank Misselwitz brings extensive experience in clinical trial execution and drug development to the company, and will provide strategic guidance to the creation of AI technology that uncovers unknown patient needs to generate the deepest possible understanding of how humans suffer from disease. The company’s ultimate goal is to generate patient experience insights on a greater scale and with more ease for new therapies and to improve the quality of care for billions: one disease at a time.

contact: Jannis Johannmeier
phone: +49(0) 172 5270504

Record changed: 2020-11-30


Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

More documents for Semalytix GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top